Core Viewpoint - A class action securities lawsuit has been filed against Replimune Group, Inc. due to alleged securities fraud affecting investors between November 22, 2024, and July 21, 2025 [1][2] Group 1: Lawsuit Details - The complaint alleges that defendants made false statements regarding the IGNYTE trial, overstating its prospects despite known material issues, leading to the FDA deeming the trial inadequate [2] - Defendants' statements about Replimune's business and operations were claimed to be materially false and misleading, lacking a reasonable basis at all relevant times [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a 20-year history of securing hundreds of millions for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4]

Core Viewpoint - A class action securities lawsuit has been filed against Replimune Group, Inc. for alleged securities fraud affecting investors between November 22, 2024, and July 21, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements regarding the IGNYTE trial's prospects, which were known to be inadequate by the defendants, leading to misleading statements about Replimune's business and operations [2]. - The complaint highlights that the FDA deemed the IGNYTE trial inadequate and not well-controlled, which contradicts the defendants' public statements [2]. Group 2: Investor Information - Investors who suffered losses during the specified period have until September 22, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, ensuring no financial obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

NEW YORK, July 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/replimune-group-inc-loss-submission-form-3/?id=158801&from=4 DEADLINE: September ...

Group 1 - China Biopharmaceutical (1177.HK) saw a rise of over 3% after announcing a successful licensing agreement with Merck for its PD-1/VEGF dual antibody, expecting a $300 million milestone payment soon [1] - CSPC Pharmaceutical Group (1093.HK) increased by over 5% following the announcement of an exclusive licensing agreement with Madrigal Pharmaceuticals for the global development of its GLP-1 receptor agonist SYH2086 [1] - Youzan (8083.HK) surged over 7% as it projected a revenue of approximately 709 to 719 million RMB for the first half of the year, a year-on-year increase of about 3.3% to 4.8%, and a net profit of 68 to 74 million RMB, marking a turnaround from a loss last year [1] Group 2 - Xingsheng International (6058.HK) rose nearly 18% after the bank announced its commitment to embrace technological transformation and explore stablecoins and AI initiatives [2] - New Oriental Education (9901.HK) fell nearly 4% after reporting a 9.4% year-on-year increase in net revenue to $1.243 billion for the fourth quarter of fiscal year 2025, but a 73.7% drop in net profit [2] - Kingdee International (0268.HK) saw a rise of over 7% as it announced a board meeting to review its interim results and potential dividend distribution [2] Group 3 - Macau gaming stocks rose, with MGM China (2282.HK) up over 4% after Macquarie raised its forecast for Macau's total gaming revenue for 2025 by 5% to 235.7 billion RMB, indicating a year-on-year growth of 4% [3] - Gold stocks in Hong Kong continued to decline, with Tongguan Gold (0340.HK) dropping over 9% for six consecutive days, as spot gold prices fell below $3,270 per ounce [4] - Kangfang Biopharma (9926.HK) rose nearly 5% after announcing the completion of the first patient dosing in a pivotal clinical trial for its PD-1/VEGF dual-specific antibody [4] Group 4 - Weishi Jiajie (0856.HK) increased by over 3% as a report indicated that its Southeast Asia business is expected to see a significant revenue increase of 74% in 2024, with net profit contributing about 51% [5] Group 5 - Meta (META.US) exceeded revenue expectations and provided strong guidance for the current quarter, leading to an after-hours increase of over 11% [6] - Microsoft (MSFT.US) reported an 18% year-on-year growth in revenue, driven by its cloud business, with Azure revenue up 34% for the full year, resulting in an after-hours increase of over 8% [6] - Wingstop (WING.US) surged by 26.85% after reporting adjusted earnings per share of $1.00 for the second quarter, exceeding analyst expectations [6] Group 6 - Several biopharmaceutical stocks surged, with Replimune (REPL.US) up 101.33% following news of regulatory changes at the FDA that may ease pressure on gene therapy and vaccine companies [7] - Marvell Technology (MRVL.US) rose 7.07% after announcing a partnership with Rebellions to provide AI systems for regional projects in Asia-Pacific and the Middle East [7] - Palo Alto Networks (PANW.US) fell 5.58% after agreeing to acquire CyberArk Software for approximately $25 billion [8]

周三，部分生物制药公司股价飙升，截至发稿，Replimune(REPL.US)飙升逾85%， Sarepta Therapeutics (SRPT.US)上涨超16%， Capricor Therapeutics(CAPR.US)大涨超18%。消息面上，美国FDA生物制品评 估与研究中心主任普拉萨德在上任不到三个月后离职，正值FDA对多款基因疗法和疫苗采取严格监管措 施，引发市场关注。分析人士指出，他的离任可能有助于缓解监管压力，被视为基因疗法和疫苗企业的 利好消息。 ...

智通财经APP获悉，周三，部分生物制药公司股价飙升，截至发稿，Replimune(REPL.US)飙升逾85%， Sarepta Therapeutics (SRPT.US)上涨超16%，Capricor Therapeutics(CAPR.US)大涨超18%。消息面上，美 国FDA生物制品评估与研究中心主任普拉萨德在上任不到三个月后离职，正值FDA对多款基因疗法和疫 苗采取严格监管措施，引发市场关注。分析人士指出，他的离任可能有助于缓解监管压力，被视为基因 疗法和疫苗企业的利好消息。 ...

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Replimune, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/replimune-group-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to b ...

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Replimune Group, Inc. (NASDAQ: REPL) securities during the specified period, alleging that the company misled investors regarding the viability of its IGNYTE trial [1][2]. Group 1: Allegations and Legal Proceedings - The lawsuit claims that Replimune Group, Inc. failed to disclose significant issues regarding the IGNYTE trial, which led to the FDA deeming the trial inadequate and not well-controlled [2]. - It is alleged that the defendants overstated the prospects of the IGNYTE trial, resulting in materially false and misleading statements about Replimune's business and operations [2]. - Following the announcement of a complete response letter (CRL) from the FDA on July 22, 2025, which indicated that the IGNYTE trial did not provide substantial evidence of effectiveness, Replimune's stock price fell by $9.52 per share, or 77.24%, closing at $2.80 per share [3]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by September 22, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 3: Company Background - Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing and commercializing oncolytic immunotherapies for cancer treatment [1]. - Robbins LLP has been recognized for its efforts in shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance since 2002 [5].

Group 1 - A securities class action lawsuit has been filed against Replimune Group, Inc. alleging possible securities fraud or other unlawful business practices [5] - The lawsuit covers a class period from November 22, 2024, to July 21, 2025, with a lead plaintiff deadline of September 22, 2025 [5] - The trigger event for the lawsuit was the FDA's Complete Response Letter rejecting Replimune's Biologics License Application for RP1, citing inadequate clinical evidence from the IGNYTE trial [5] Group 2 - Following the FDA's announcement, Replimune's stock experienced a significant decline of 77.24%, closing at $2.81 per share after a drop of $9.52 [5]

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Replimune Group, Inc. securities for the period between November 22, 2024, and July 21, 2025, due to alleged misleading statements regarding the IGNYTE trial [1][5]. Group 1: Lawsuit Details - The lawsuit claims that defendants made materially false and misleading statements about the IGNYTE trial's prospects, which led to the FDA deeming the trial inadequate [5]. - Investors who purchased Replimune securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by September 22, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has consistently ranked among the top firms in this area since 2013 [4].